EGLT - Egalet Corporation

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of EGLT earnings conference call or presentation 16-May-19 8:30pm GMT

    Q1 2019 Egalet Corp Earnings Call

  • Associated Press7 months ago

    Egalet: 3Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 93 cents per share. Losses, adjusted for one-time gains and costs, were 75 cents per share. The pain medicine maker posted revenue of $8.2 million ...

  • Egalet Reports Third Quarter 2018 Financial Results
    PR Newswire7 months ago

    Egalet Reports Third Quarter 2018 Financial Results

    -- Highest quarterly revenue for SPRIX Nasal Spray and OXAYDO -- WAYNE, Pa. , Nov. 19, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical ...

  • Will Egalet (EGLTQ) Report Negative Earnings Next Week? What You Should Know
    Zacks7 months ago

    Will Egalet (EGLTQ) Report Negative Earnings Next Week? What You Should Know

    Egalet (EGLTQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks Small Cap Research8 months ago

    EGLT: Egalet Recapitalization

    On October 31, 2018 Egalet Corp (EGLT) announced that it has signed a purchase agreement to acquire several pain products from Iroko Pharmaceuticals, Inc. (private). With insufficient cash to satisfy the outstanding debt, Egalet entered into forbearance with noteholders leading to the Chapter 11 filing. If the proposed asset purchase agreement is approved, Egalet will acquire several assets from Iroko, including Vivlodex, Tivorbex, Zorvolex, Indocin and an in-development NSAID.

  • Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products
    PR Newswire8 months ago

    Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

    WAYNE, Pa., Oct. 31, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, today entered into an asset purchase agreement to acquire four marketed products from Iroko Pharmaceuticals, Inc. (Iroko). If consummated, the proposed transaction will enable Egalet to focus on marketing predominantly non-narcotic pain products. To facilitate this transaction and reorganize Egalet's capital structure, Egalet has initiated proceedings under Chapter 11 of the United States Bankruptcy Code in the District of Delaware.

  • Zacks Small Cap Research10 months ago

    EGLT: Egalet 2Q:18 Results

    Egalet Corporation (EGLT) released second quarter 2018 results on August 8 and filed form 10-Q on August 9 posting revenues of $7.4 million and a net loss of ($0.22) per share. The company continues to develop partnerships and add products to preferred formulary positions adding several new PBMs and plans to its portfolio. Second quarter revenues of $7.4 million were comprised of Sprix sales of $5.4 million, Oxaydo sales of $1.7 million and Arymo sales of $0.4 million.

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of EGLT earnings conference call or presentation 8-Aug-18 12:30pm GMT

    Q2 2018 Egalet Corp Earnings Call

  • ACCESSWIRE10 months ago

    Egalet Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Egalet Corporation (NASDAQ: EGLT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern Time. ...

  • Associated Press10 months ago

    Egalet: 2Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The pain medicine maker posted revenue of $7.4 million ...

  • Egalet Reports Second Quarter 2018 Financial Results
    PR Newswire10 months ago

    Egalet Reports Second Quarter 2018 Financial Results

    --Improvements in formulary status for key products-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , Aug. 8, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), ...

  • Benzinga10 months ago

    Preview: Egalet's Q2 Earnings

    On Wednesday,  Egalet (NASDAQ: EGLT ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Egalet EPS will likely ...

  • Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018
    PR Newswire11 months ago

    Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018

    WAYNE, Penn., July 25, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.